ErbB3 expression predicts sensitivity to elisidepsin treatment: In vitro synergism with cisplatin, paclitaxel and gemcitabine in lung, breast and colon cancer cell lines

International Journal of Oncology

Volumn 41, Issue 1, 2012, Pages 317-324

  Teixidó, Cristina ^a   Arguelaguet, Elisabet ^a   Pons, Berta ^a   Aracil, Miguel ^b   Jimeno, Jose ^b,c   Somoza, Rosa ^a   Marés, Roso ^a   Ramón Y Cajal, Santiago ^a   Hernández Losa, Javier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b PHARMAMAR S A   (Spain)

^c INSTITUT UNIVERSITARI DEXEUS   (Spain)

Author keywords

Cisplatin; Elisidepsin; ErbB3; Gemcitabine; Paclitaxel

Indexed keywords

CISPLATIN; ELISIDEPSIN; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN KINASE B;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; CORRELATION COEFFICIENT; DOWN REGULATION; DRUG EFFECT; DRUG POTENTIATION; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; LUNG CARCINOMA; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; COLONIC NEOPLASMS; DEOXYCYTIDINE; DEPSIPEPTIDES; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASES; PACLITAXEL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3;

EID: 84862870400     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1425     Document Type: Article

References (35)

1. Carter NJ and Keam SJ: Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs 70: 355-376, 2010.
2. Hamann MT, Otto CS, Scheuer PJ and Dunbar DC: Kahalalides: bioactive peptides from a marine mollusk elysia rufescens and its algal diet bryopsis sp.(1). J Org Chem 61: 6594-6600, 1996. (Pubitemid 26328646)
3. Wosikowski K, Schuurhuis D, Johnson K, et al: Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J Natl Cancer Inst 89: 1505-1515, 1997. (Pubitemid 27441175)
4. Gomez SG, Bueren JA, Faircloth GT, Jimeno J and Albella B: In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells. Exp Hematol 31: 1104-1111, 2003. (Pubitemid 37329755)
5. Suarez Y, Gonzalez L, Cuadrado A, Berciano M, Lafarga M and Munoz A: Kahalalide F, a new marine-derived compound, induces oncosis in human prostate and breast cancer cells. Mol Cancer Ther 2: 863-872, 2003.
6. Yin J, Aviles P, Lee W, et al: Development of a liquid chromatography/tandem mass spectrometry assay for the quantification of PM02734, a novel antineoplastic agent, in dog plasma. Rapid Commun Mass Spectrom 20: 2735-2740, 2006. (Pubitemid 44497403)
7. Rademaker-Lakhai JM, Horenblas S, Meinhardt W, et al: Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer. Clin Cancer Res 11: 1854-1862, 2005. (Pubitemid 40471850)
8. Pardo B, Paz-Ares L, Tabernero J, et al: Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors. Clin Cancer Res 14: 1116-1123, 2008. (Pubitemid 351302559)
9. Chandarlapaty S, Scaltriti M, Angelini P, et al: Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 29: 325-334, 2010.
10. Herrero AB, Astudillo AM, Balboa MA, Cuevas C, Balsinde J and Moreno S: Levels of SCS7/FA2H-mediated fatty acid 2-hydroxylation determine the sensitivity of cells to antitumor PM02734. Cancer Res 68: 9779-9787, 2008.
11. Coussens L, Yang-Feng TL, Liao YC, et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132-1139, 1985. (Pubitemid 16169997)
12. Janmaat ML, Rodriguez JA, Jimeno J, Kruyt FA and Giaccone G: Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol Pharmacol 68: 502-510, 2005. (Pubitemid 41058313)
13. Ling YH, Aracil M, Jimeno J, Perez-Soler R and Zou Y: Molecular pharmacodynamics of PM02734 (elisidepsin) as single agent and in combination with erlotinib; synergistic activity in human non-small cell lung cancer cell lines and xenograft models. Eur J Cancer 45: 1855-1864, 2009.
14. Trimmer EE and Essigmann JM: Cisplatin. Essays Biochem 34: 191-211, 1999. (Pubitemid 129638938)
15. Gonzalez VM, Fuertes MA, Alonso C and Perez JM: Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol 59: 657-663, 2001. (Pubitemid 32273993)
16. Blagosklonny MV and Fojo T: Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 83: 151-156, 1999. (Pubitemid 29449089)
17. Hortobagyi GN: Recent progress in the clinical development of docetaxel (Taxotere). Semin Oncol 26: 32-36, 1999.
18. Schwartz J: Current combination chemotherapy regimens for metastatic breast cancer. Am J Health Syst Pharm 66: S3-S8, 2009.
19. Raez LE, Kobina S and Santos ES: Oxaliplatin in first-line therapy for advanced non-small cell lung cancer. Clin Lung Cancer 11: 18-24, 2010.
20. Squadroni M and Fazio N: Chemotherapy in pancreatic adenocarcinoma. Eur Rev Med Pharmacol Sci 14: 386-394, 2010.
21. Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
22. Shilabin AG, Kasanah N, Wedge DE and Hamann MT: Lysosome and HER3 (ErbB3) selective anticancer agent kahalalide F: semisynthetic modifications and antifungal lead-exploration studies. J Med Chem 50: 4340-4350, 2007. (Pubitemid 47378833)
23. Hama H, Young DA, Radding JA, et al: Requirement of sphingolipid α-hydroxylation for fungicidal action of syringomycin E. FEBS Lett 478: 26-28, 2000. (Pubitemid 30462252)
24. Kourie JI and Shorthouse AA: Properties of cytotoxic peptide-formed ion channels. Am J Physiol Cell Physiol 278: C1063-C1087, 2000. (Pubitemid 30432391)
25. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF III and Hynes NE: The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci USA 100: 8933-8938, 2003. (Pubitemid 36899201)
26. Alimandi M, Romano A, Curia MC, et al: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10: 1813-1821, 1995.
27. Wallasch C, Weiss FU, Niederfellner G, Jallal B, Issing W and Ullrich A: Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. EMBO J 14: 4267-4275, 1995.
28. Prigent SA and Gullick WJ: Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 13: 2831-2841, 1994.
29. Burgering BM and Coffer PJ: Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376: 599-602, 1995.
30. Menendez JA, Mehmi I, Atlas E, Colomer R and Lupu R: Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-κB. Int J Oncol 24: 591-608, 2004.
31. Hirsch DS, Shen Y and Wu WJ: Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42. Cancer Res 66: 3523-3530, 2006.
32. Biscardi JS, Belsches AP and Parsons SJ: Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells. Mol Carcinog 21: 261-272, 1998. (Pubitemid 28208747)
33. Xue C, Liang F, Mahmood R, et al: ErbB3-dependent motility and intravasation in breast cancer metastasis. Cancer Res 66: 1418-1426, 2006. (Pubitemid 43259922)
34. Sun M, Behrens C, Feng L, et al: HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res 15: 4829-4837, 2009.
35. Váradi T, Roszik J, Lisboa D, et al: ErbB protein modifications are secondary to severe cell membrane alterations induced by elisidepsin treatment. Eur J Pharmacol 667: 91-99, 2011.